questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
Phosphotransferases
Transferases (other substituted phosphate groups)
Transferases (other substituted phosphate groups) : Questions médicales fréquentes
Termes MeSH sélectionnés :
Sensitivity and Specificity
Diagnostic
5
Déficience enzymatique
Tests de laboratoire
Analyse biochimique
Tests génétiques
Symptômes
Troubles métaboliques
Tests sanguins
Activité enzymatique
Symptômes
5
Symptômes
Troubles neurologiques
Types d'enzymes
Symptômes
Évolution des symptômes
Conditions sous-jacentes
Symptômes
Déficience enzymatique
Fatigue
Douleurs musculaires
Prévention
5
Conseils nutritionnels
Vitamines
Exercice physique
Métabolisme
Facteurs environnementaux
Toxiques
Traitements
5
Traitement
Suppléments enzymatiques
Médicaments
Régulation enzymatique
Thérapie génique
Déficiences enzymatiques
Traitements personnalisés
Déficiences enzymatiques
Complications
5
Complications
Troubles métaboliques
Qualité de vie
Limitations fonctionnelles
Fréquence
Déficiences enzymatiques
Complications à long terme
Déficiences
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Âge
Troubles enzymatiques
Maladies génétiques
Déficiences enzymatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Transferases (other substituted phosphate groups) : Questions médicales les plus fréquentes",
"headline": "Transferases (other substituted phosphate groups) : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Transferases (other substituted phosphate groups) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-30",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Transferases (other substituted phosphate groups)"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phosphotransferases",
"url": "https://questionsmedicales.fr/mesh/D010770",
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases",
"code": {
"@type": "MedicalCode",
"code": "D010770",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "CDP-diacylglycerol-inositol 3-phosphatidyltransferase",
"alternateName": "CDP-Diacylglycerol-Inositol 3-Phosphatidyltransferase",
"url": "https://questionsmedicales.fr/mesh/D051607",
"about": {
"@type": "MedicalCondition",
"name": "CDP-diacylglycerol-inositol 3-phosphatidyltransferase",
"code": {
"@type": "MedicalCode",
"code": "D051607",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.900.074"
}
}
},
{
"@type": "MedicalWebPage",
"name": "CDPdiacylglycerol-serine O-phosphatidyltransferase",
"alternateName": "CDPdiacylglycerol-Serine O-Phosphatidyltransferase",
"url": "https://questionsmedicales.fr/mesh/D010717",
"about": {
"@type": "MedicalCondition",
"name": "CDPdiacylglycerol-serine O-phosphatidyltransferase",
"code": {
"@type": "MedicalCode",
"code": "D010717",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.900.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cholinephosphotransferase",
"alternateName": "Diacylglycerol Cholinephosphotransferase",
"url": "https://questionsmedicales.fr/mesh/D002798",
"about": {
"@type": "MedicalCondition",
"name": "Cholinephosphotransferase",
"code": {
"@type": "MedicalCode",
"code": "D002798",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.900.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ethanolaminephosphotransferase",
"alternateName": "Ethanolaminephosphotransferase",
"url": "https://questionsmedicales.fr/mesh/D004982",
"about": {
"@type": "MedicalCondition",
"name": "Ethanolaminephosphotransferase",
"code": {
"@type": "MedicalCode",
"code": "D004982",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.900.250"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Transferases (other substituted phosphate groups)",
"alternateName": "Transferases (Other Substituted Phosphate Groups)",
"code": {
"@type": "MedicalCode",
"code": "D017855",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Maja Antunović",
"url": "https://questionsmedicales.fr/author/Maja%20Antunovi%C4%87",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 19, p.p.177, HR-10001 Zagreb, Croatia."
}
},
{
"@type": "Person",
"name": "Marica Ivanković",
"url": "https://questionsmedicales.fr/author/Marica%20Ivankovi%C4%87",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 19, p.p.177, HR-10001 Zagreb, Croatia."
}
},
{
"@type": "Person",
"name": "Hrvoje Ivanković",
"url": "https://questionsmedicales.fr/author/Hrvoje%20Ivankovi%C4%87",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 19, p.p.177, HR-10001 Zagreb, Croatia."
}
},
{
"@type": "Person",
"name": "Inna V Fadeeva",
"url": "https://questionsmedicales.fr/author/Inna%20V%20Fadeeva",
"affiliation": {
"@type": "Organization",
"name": "A.A. Baikov Institute of Metallurgy and Material Science RAS, Leninskie, 49, 119334 Moscow, Russia."
}
},
{
"@type": "Person",
"name": "Julietta V Rau",
"url": "https://questionsmedicales.fr/author/Julietta%20V%20Rau",
"affiliation": {
"@type": "Organization",
"name": "Department of Analytical, Physical and Colloid Chemistry, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University, Trubetskaya 8, Build. 2, 119991 Moscow, Russia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "AUCReshaping: improved sensitivity at high-specificity.",
"datePublished": "2023-11-30",
"url": "https://questionsmedicales.fr/article/38036602",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-48482-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Meta-analysis assessing the sensitivity and specificity of",
"datePublished": "2023-03-18",
"url": "https://questionsmedicales.fr/article/36934977",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ahj.2023.03.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sensitivity and specificity of Varian Halcyon's portal dosimetry for plan-specific pre-treatment QA.",
"datePublished": "2023-04-22",
"url": "https://questionsmedicales.fr/article/37086428",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/acm2.14001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Specific recognition and sensitive quantification of mRNA splice variants",
"datePublished": "2023-11-06",
"url": "https://questionsmedicales.fr/article/37818948",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d3an01382k"
}
},
{
"@type": "ScholarlyArticle",
"name": "Estimating stage-specific sensitivity for cancer screening tests.",
"datePublished": "2023-02-03",
"url": "https://questionsmedicales.fr/article/36734139",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/09691413231154801"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Phosphotransferases",
"item": "https://questionsmedicales.fr/mesh/D010770"
},
{
"@type": "ListItem",
"position": 6,
"name": "Transferases (other substituted phosphate groups)",
"item": "https://questionsmedicales.fr/mesh/D017855"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Transferases (other substituted phosphate groups) - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Transferases (other substituted phosphate groups)",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Transferases (other substituted phosphate groups)",
"description": "Comment diagnostiquer une déficience en transferases ?\nQuels examens sont utilisés pour évaluer les transferases ?\nQuels symptômes indiquent un problème de transferases ?\nLes transferases sont-elles mesurables dans le sang ?\nQuel rôle jouent les transferases dans le métabolisme ?",
"url": "https://questionsmedicales.fr/mesh/D017855?mesh_terms=Sensitivity+and+Specificity#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Transferases (other substituted phosphate groups)",
"description": "Quels symptômes sont liés à une activité anormale des transferases ?\nLes symptômes varient-ils selon le type de transferase ?\nComment les symptômes évoluent-ils avec le temps ?\nLes symptômes sont-ils toujours présents ?\nY a-t-il des symptômes spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D017855?mesh_terms=Sensitivity+and+Specificity#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Transferases (other substituted phosphate groups)",
"description": "Peut-on prévenir les troubles liés aux transferases ?\nQuels conseils nutritionnels pour prévenir les troubles ?\nLes dépistages sont-ils recommandés ?\nL'exercice physique aide-t-il à prévenir les troubles ?\nY a-t-il des facteurs environnementaux à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D017855?mesh_terms=Sensitivity+and+Specificity#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Transferases (other substituted phosphate groups)",
"description": "Quels traitements existent pour les déficiences en transferases ?\nLes médicaments peuvent-ils aider à réguler les transferases ?\nLa thérapie génique est-elle une option ?\nComment la nutrition influence-t-elle les transferases ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D017855?mesh_terms=Sensitivity+and+Specificity#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Transferases (other substituted phosphate groups)",
"description": "Quelles complications peuvent survenir avec des déficiences en transferases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles fréquentes ?\nY a-t-il des complications à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D017855?mesh_terms=Sensitivity+and+Specificity#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Transferases (other substituted phosphate groups)",
"description": "Quels sont les facteurs de risque pour les troubles des transferases ?\nL'âge influence-t-il le risque de troubles ?\nLes maladies génétiques augmentent-elles le risque ?\nLe mode de vie joue-t-il un rôle dans le risque ?\nY a-t-il des risques liés à l'environnement ?",
"url": "https://questionsmedicales.fr/mesh/D017855?mesh_terms=Sensitivity+and+Specificity#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en transferases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques sanguins peuvent mesurer l'activité des transferases."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer les transferases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les analyses biochimiques et les tests génétiques sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème de transferases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des douleurs musculaires ou des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les transferases sont-elles mesurables dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité des transferases peut être mesurée dans des échantillons sanguins."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les transferases dans le métabolisme ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont essentielles pour le transfert de groupes phosphate, influençant le métabolisme cellulaire."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une activité anormale des transferases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs musculaires, fatigue ou troubles neurologiques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de transferase ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque type de transferase peut entraîner des symptômes spécifiques selon son rôle."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver si la condition sous-jacente n'est pas traitée."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent avoir des périodes sans symptômes malgré une déficience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, surveiller la fatigue excessive et les douleurs musculaires est crucial."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux transferases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines déficiences peuvent être évitées par une alimentation adéquate et un suivi médical."
}
},
{
"@type": "Question",
"name": "Quels conseils nutritionnels pour prévenir les troubles ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consommer des aliments riches en vitamines et minéraux peut aider à maintenir l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Les dépistages sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages réguliers peuvent aider à identifier les problèmes précocement."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir les troubles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer le métabolisme et l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à surveiller ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains toxiques environnementaux peuvent affecter l'activité des transferases."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les déficiences en transferases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments enzymatiques ou des modifications diététiques."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à réguler les transferases ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aider à normaliser l'activité des transferases."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche pour traiter certaines déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle les transferases ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir l'activité enzymatique et le métabolisme."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés selon le type de déficience et les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des déficiences en transferases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des troubles métaboliques graves ou des maladies neurologiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en provoquant des douleurs et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fréquence des complications dépend du type de déficience et de la prise en charge."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences peuvent entraîner des complications chroniques si non traitées."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles des transferases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, les maladies métaboliques et certains régimes alimentaires sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de troubles ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles enzymatiques sont plus fréquents chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques peuvent prédisposer à des déficiences en transferases."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle dans le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques liés à l'environnement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut affecter l'activité des transferases."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 24/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 19, p.p.177, HR-10001 Zagreb, Croatia.
Publications dans "Transferases (other substituted phosphate groups)" :
3 publications dans cette catégorie
Affiliations :
Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 19, p.p.177, HR-10001 Zagreb, Croatia.
Publications dans "Transferases (other substituted phosphate groups)" :
3 publications dans cette catégorie
Affiliations :
Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 19, p.p.177, HR-10001 Zagreb, Croatia.
Publications dans "Transferases (other substituted phosphate groups)" :
3 publications dans cette catégorie
Affiliations :
A.A. Baikov Institute of Metallurgy and Material Science RAS, Leninskie, 49, 119334 Moscow, Russia.
Publications dans "Transferases (other substituted phosphate groups)" :
3 publications dans cette catégorie
Affiliations :
Department of Analytical, Physical and Colloid Chemistry, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University, Trubetskaya 8, Build. 2, 119991 Moscow, Russia.
Istituto di Struttura della Materia, Consiglio Nazionale delle Ricerche (ISM-CNR), Via del Fosso del Cavaliere, 100-00133 Rome, Italy.
Publications dans "Transferases (other substituted phosphate groups)" :
2 publications dans cette catégorie
Affiliations :
Division of Craniofacial Function Engineering, Tohoku University Graduate School of Dentistry.
Publications dans "Transferases (other substituted phosphate groups)" :
2 publications dans cette catégorie
Affiliations :
Division of Craniofacial Function Engineering, Tohoku University Graduate School of Dentistry.
Publications dans "Transferases (other substituted phosphate groups)" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain.
Publications dans "Transferases (other substituted phosphate groups)" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain.
Program of Predictive and Personalized Medicine of Cancer (PMPPC), Institut d'Investigació Germans Trias i Pujol (IGTP), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain.
Publications dans "Transferases (other substituted phosphate groups)" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain. fyamamoto@carrerasresearch.org.
Program of Predictive and Personalized Medicine of Cancer (PMPPC), Institut d'Investigació Germans Trias i Pujol (IGTP), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain. fyamamoto@carrerasresearch.org.
Publications dans "Transferases (other substituted phosphate groups)" :
2 publications dans cette catégorie
Affiliations :
Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 19, p.p.177, HR-10001 Zagreb, Croatia.
Publications dans "Transferases (other substituted phosphate groups)" :
2 publications dans cette catégorie
Affiliations :
Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 19, p.p.177, HR-10001 Zagreb, Croatia.
Publications dans "Transferases (other substituted phosphate groups)" :
2 publications dans cette catégorie
Affiliations :
Department of Mechanical and Aerospace Engineering, University of California, Irvine, Engineering Gateway 4200, Irvine, California 92697, United States.
Publications dans "Transferases (other substituted phosphate groups)" :
1 publication dans cette catégorie
Affiliations :
Division of Craniofacial Function Engineering, Tohoku University Graduate School of Dentistry.
Publications dans "Transferases (other substituted phosphate groups)" :
1 publication dans cette catégorie
Affiliations :
Laboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain.
Biologia Molecolare, Università degli Studi di Parma, Parma, 43121, Italy.
Publications dans "Transferases (other substituted phosphate groups)" :
1 publication dans cette catégorie
Affiliations :
Laboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain.
Laboratory of Molecular Microbiological Science, Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima, 737-0112, Japan.
Publications dans "Transferases (other substituted phosphate groups)" :
1 publication dans cette catégorie
Affiliations :
Faraday Materials Laboratory (FaMaL), Materials Research Centre, Indian Institute of Science, Bangalore 560012, India.
Publications dans "Transferases (other substituted phosphate groups)" :
1 publication dans cette catégorie
Affiliations :
Faraday Materials Laboratory (FaMaL), Materials Research Centre, Indian Institute of Science, Bangalore 560012, India.
Publications dans "Transferases (other substituted phosphate groups)" :
1 publication dans cette catégorie
Affiliations :
Materials Theory for Energy Scavenging (MATES) Lab, Harish-Chandra Research Institute (HRI), A C.I. of Homi Bhabha National Institute (HBNI), Chhatnag Road, Jhunsi, Prayagraj 211019, India.
Publications dans "Transferases (other substituted phosphate groups)" :
1 publication dans cette catégorie
Affiliations :
Materials Research Centre, Indian Institute of Science, Bangalore 560012, India.
Publications dans "Transferases (other substituted phosphate groups)" :
The evaluation of deep-learning (DL) systems typically relies on the Area under the Receiver-Operating-Curve (AU-ROC) as a performance metric. However, AU-ROC, in its holistic form, does not sufficien...
The use of...
To estimate the summary sensitivity and specificity of...
Studies were included if PET/CT was performed for suspicion of PVE and IPD of both the PET/CT result and final diagnosis defined by a gold-standard assessment was available. There were 3 possible fina...
Seventeen studies were included with IPD available for 537 patients (from 538 scans). The summary sensitivity and specificity were 85% (95% CI 74.2%-91.8%) and 86.5% (95% CI 75.8%-92.9%) respectively ...
Developed as a plan-specific pre-treatment QA tool, Varian portal dosimetry promises a fast, high-resolution, and integrated QA solution. In this study, the agreement between predicted fluence and mea...
All patient plans and the corresponding verification plans were generated within the Eclipse treatment planning system. Four representative plans of different treatment sites (prostate, prostate with ...
Predicted and acquired portal dosimetry fluences demonstrated a high agreement evident by average gamma passing rates for the clinical patient plans of 99.90%, 96.64%, and 91.87% for γ...
Owing to the high achievable spatial resolution, portal dosimetry at the Halcyon can reliably be deployed as plan-specific pre-treatment QA tool to screen for errors. It is recommended to support the ...
Specific recognition and sensitive quantification of mRNA alternative splice variants have been a necessity for exploring the regulatory mechanism of RNA splicing and revealing the association between...
When evaluating potential new cancer screening modalities, estimating sensitivity, especially for early-stage cases, is critical. There are methods to approximate stage-specific sensitivity in asympto...
We fit natural history models to lung and ovarian cancer screening data that permitted estimation of stage-specific (early/late) true sensitivity, defined as the probability subjects screened in the g...
Stage-specific true sensitivities estimated by the lung cancer natural history model were 47% (early) and 63% (late). Simulation results for the prospective setting gave estimated sensitivities of 81%...
Existing methods for approximating stage-specific sensitivity in both prospective and retrospective scenarios are unsatisfactory; improvements are needed before they can be considered to be reliable....
Recombinant proteins in complex solutions are typically detected with tag-specific antibodies in Western blots. Here we describe an antibody-free alternative in which tagged proteins are detected dire...
Children with cancer often present with general and nonspecific symptoms leading to initial diagnostic workup inclusive of clinical imaging. Various sequences of magnetic resonance imaging (MRI) are b...
Enzyme-linked immunosorbent assays (ELISAs) are a cornerstone of modern molecular detection, but the technique still faces notable challenges. One of the biggest problems is discriminating true signal...
To evaluate the sensitivity and specificity of the ABCD progression display for keratoconus progression....
Data was collected from patients that underwent at least two Pentacam assessments 6 months apart. Sensitivity and specificity were calculated for the ABCD progression display. Progression was defined ...
Thirty eyes were evaluated over a median time of 10.3 months. Progression by criterion 1 resulted in a sensitivity of 61.9% and specificity of 88.9%. Progression by criterion 2 resulted in higher sens...
The ABCD progression display can assess keratoconus progression with high sensitivity and specificity, thus assisting the patients' decision-making process. The D parameter did not contribute to the s...
To systematically evaluate the evidence for the reliability, sensitivity and specificity of existing measures of vowel-initial voice onset....
A literature search was conducted across electronic databases for published studies (MEDLINE, EMBASE, Scopus, Web of Science, CINAHL, PubMed Central, IEEE Xplore) and grey literature (ProQuest for unp...
The search retrieved 6,983 records. Titles and abstracts were screened against the inclusion criteria by two independent reviewers, with a third reviewer responsible for conflict resolution. Thirty-fi...
A range of vowel-initial voice onset measurements have been applied throughout the literature, however, there is a lack of evidence regarding their sensitivity, specificity and reliability in the dete...